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Abstract
Assays to determine cross-sectional HIV incidence misclassify some individuals with nonrecent HIV infection as
recentlyinfected,overestimatingHIVincidence.Weanalyzedfactorsassociatedwithfalse-recentmisclassiﬁcationin
ﬁve African countries. Samples from 2197 adults from Botswana, Kenya, South Africa, Tanzania, and Uganda who
were HIV infected >12 months were tested using the (1) BED capture enzyme immunoassay (BED), (2) avidity
assay, (3) BED and avidity assays with higher assay cutoffs (BED+avidity screen), and (4) multiassay algorithm
(MAA) that includes the BED+avidity screen, CD4cell count, and HIV viral load. Logistic regression identiﬁed
factors associated with misclassiﬁcation. False-recent misclassiﬁcation rates and 95% conﬁdence intervals were BED
alone: 7.6% (6.6, 8.8); avidity assay alone: 3.5% (2.7, 4.3); BED+avidity screen: 2.2% (1.7, 2.9); and MAA: 1.2% (0.8,
1.8). The misclassiﬁcation rate for the MAA was signiﬁcantly lower than the rates for the other three methods (each
p<0.05). Misclassiﬁcation rates were lower when the analysis was limited to subtype C-endemic countries, with the
lowest rate obtained for the MAA [0.8% (0.2, 1.9)]. Factors associated with misclassiﬁcation were for BED alone:
country of origin, antiretroviral treatment (ART), viral load, and CD4cell count; for avidity assay alone: country of
origin; for BED+avidity screen: country of origin and ART. No factors were associated with misclassiﬁcation using
theMAA.Inamultivariatemodel,theseassociationsremainedsigniﬁcantwithoneexception:theassociationofART
with misclassiﬁcation was completely attenuated. A MAA that included CD4cell count and viral load had lower
false-recent misclassiﬁcation than the BED or avidity assays (alone or in combination). Studies are underway to
compare the sensitivity of these methods for detection of recent HIV infection.
Introduction
A
ccurate methods for cross-sectional HIV incidence
determination are needed to monitor the HIV/AIDS
epidemic and to evaluate the effectiveness of interventions for
HIV prevention.
1 These methods would also enable use of
cross-sectional surveys to estimate HIV incidence for pre-
vention studies in populations at high risk of HIV acquisition.
Most laboratory tests that are currently used to estimate HIV
incidence are based on analysis of anti-HIV antibodies.
2,3 One
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1177widely used method is the BED capture enzyme immunoas-
say (BED-CEIA), which measures the proportion of all IgG
antibodies that bind to an HIV peptide.
4 Recently, an avidity
assay has been developed for HIV incidence determination
thatisbasedontheBioRad1/2+OELISAtest.
5Thecapacities
of these assays to identify recently infected individuals are
described elsewhere.
5,6
A critical limitation of the BED-CEIA for HIV incidence
determination is that individuals with long-standing HIV
infection are often misclassiﬁed as recently infected. This type
of misclassiﬁcation can lead to a signiﬁcant overestimation of
HIV incidence rates, and has prompted the Joint United Na-
tions Programme on HIV/AIDS (UNAIDS) to discourage the
use of the BED-CEIA for HIV incidence determination.
7 Fac-
tors previously associated with misclassiﬁcation of the BED-
CEIA in African populations include low HIV viral load,
low CD4cell count, and long-term antiretroviral therapy
(ART).
8–12 However, none of those studies has compared
false-recent misclassiﬁcation among demographically similar
populations in different African countries, and little is known
about the frequency and nature of false-recent misclassiﬁca-
tion using the avidity assay, especially in an African setting.
The Incidence Assay Critical Path Working Group has re-
cently recommended using a testing algorithm for HIV inci-
dence that combines results from two different assays to
reduce misclassiﬁcation.
13 This approach was used in a recent
study from Rwanda, which demonstrated that combining the
BED-CEIA with an avidity assay based on the AxSYM limited
false-recent misclassiﬁcation while maintaining adequate
sensitivity for detection of recently infected individuals.
14
While it is important to limit misclassiﬁcation of individuals
with long-standing infection as recently infected, it is also
desirable to identify recently infected individuals, and to
maximize the length of time where laboratory assays reliably
identify infections as recent (the window period for recent
infection). The goals of this study were to compare the false-
recent misclassiﬁcation rates of four different laboratory
approaches for HIV incidence determination, and to identify
factors associated with false-recent misclassiﬁcation using
each of these testing approaches: (1) the BED-CEIA, (2) an
avidity assay, (3) the BED-CEIA and the avidity assay used
jointly with elevated assay cutoffs (BED+avidity screens),
and (4) a multiassay algorithm that included the BED+avidity
screens, as well as CD4cell count and HIV viral load. The fre-
quency of misclassiﬁcation and factors associated with mis-
classiﬁcationwereassessedbytestingsamplesobtained froma
cohort of men and women from Botswana, Kenya, South
Africa, Tanzania, and Uganda who were known to have been
infected with HIV for at least 12 months.
Materials and Methods
Samples used for analysis
Samples were obtained from 2197 HIV-infected partici-
pants in the Partners in Prevention HSV/HIV Transmission
Study,
15 a clinical trial that enrolled stable, HIV-serodiscordant
couples (one partner HIV infected and one partner HIV un-
infected) from sub-Saharan Africa to investigate the impact
of acyclovir treatment on HIV transmission. We tested sam-
ples that were collected from HIV-infected participants a
median of 21 months after enrollment (range 12–24 months).
The duration of infection was calculated based on the partic-
ipants’ report of their ﬁrst positive test date: using this ap-
proach, participants were infected a median of 25 months
(interquartile range 20–34, range 12–253). Samples were col-
lected from participants from Botswana (N=199), Kenya
(N=902), South Africa (N=330), Tanzania (N=138), and
Uganda (N=628); some samples from Uganda were obtained
from an ancillary study.
16 Epidemiologic and laboratory data,
including HIV viral load and CD4cell count, were obtained
during the trial and were included in the analysis. The use of
ART was based on self-report.
Laboratory testing
The BED-CEIA was performed according to the manufac-
turer’s instructions (Calypte Biomedical Corporation, Lake
Oswego, OR). The BED-CEIA measures the proportion of
total IgG that binds to a branched synthetic tripeptide that
contains three 18-amino acid components derived from an
immunodominant region of gp41 (regions corresponding to
positions 590–607 of HXB2 gp160 in HIV subtypes B, E, and
D).
17 Results from the BED-CEIA are reported as normalized
optical density units (OD-n). A standard assay cut-off of <0.8
OD-n was used to deﬁne recent HIV infection when the BED-
CEIA was used alone.
4 The avidity assay was performed
using a modiﬁed Genetic Systems HIV-1/HIV-2+O EIA
(enzyme linked immunoassay, Bio-Rad Laboratories, Red-
mond, WA) with diethylamine (DEA) as the chaotropic
agent.
5 An avidity index (AI) was calculated by dividing the
optical density of the DEA-treated well by the optical density
of the nontreated well for the same sample, and multiplying
by 100. A standard cut-off of <40% was used to deﬁne recent
infection when the avidity assay was used alone. When the
BED-CEIA and avidity assays were used in combination, we
used cut-offs of <1.0 OD-n (BED screen) and <80% (avidity
screen), respectively. These higher cut-off values were also
used in the multiassay algorithm (MAA); in the MAA, recent
infection wasdeﬁned as BED-CEIA <1.0 OD-n, avidity index
<80%, HIV viral load of >400copies/ml, and CD4cell count
>200cells/mm
3. The cut-offs used in the MAA were selected
by analyzing data obtained by testing samples from individ-
uals in other cohorts and clinical studies who had known
durations of HIV infection.
Statistical analysis
The misclassiﬁcation rates with exact 95% conﬁdence in-
tervals (95% CI) were calculated using BED-CEIA alone,
avidity assay alone, BED-CIEA and avidity in combination
(BED+avidity screens), and the MAA; these frequencies were
compared using Fisher’s exact test or chi-square test. The as-
sociation ofthemisclassiﬁcationratesofeachtest methodwas
assessed for age, viral load, CD4cell count, country of origin,
and ART using logistic regression.
Additionally, categories were generated based on the cir-
culating subtypes in each country (subtype C endemic: Bots-
wanaandSouthAfrica;subtypeAandDendemic:Kenyaand
Uganda; Tanzania was not included in either group because
of the heterogeneity of subtypes in that country). All factors
associated in the univariate analysis based on logistic re-
gression (p<0.1) were included in the multivariate analysis.
Multivariate logistic regression analysis was performed to
identify factors associated with misclassiﬁcation with each
method after adjustment for other factors. All statistical
1178 LAEYENDECKER ET AL.analyses were performed using STATA v11 (StataCorp,
College Station, TX).
Human subjects
All work was conducted in accordance with the Declara-
tion of Helsinki. Written consent was provided from each
participant for participation in the Partners in Prevention
Study. Experiments were conducted with the approval by the
appropriate institutional review boards.
Results
We analyzed samples from 763 men and 1434 women en-
rolled in the Partners in Prevention HSV/HIV Transmission
Study; one sample was analyzed for each of the 2197 partic-
ipants. Each participant was known to have been HIV in-
fected for at least 12 months at the time of sample collection.
Though the ages were similar between countries, the pro-
portion of female, virally suppressed, taking ART, and mean
viral load was different by country (see Table 1). Of the par-
ticipants with viral load data, 17% (488/2193) were virally
suppressed (viral load <400copies/ml). Among 1916 par-
ticipants who indicated that that they were not on ART, 275
(14%) were virally suppressed. Only 6% (142/2197) of par-
ticipants hadaCD4cellcount <200cells/mm
3,andonly0.3%
(7/2197) had a CD4cell count <50cells/mm
3. Nineteen par-
ticipants (0.8%) had a viral load <400copies/ml and a CD4
cell count <200cells/mm
3.
Table 2 presents the frequency of false-recent misclassiﬁ-
cation by the BED-CEIA (BED <0.8 OD-n), the avidity assay
(AI <40%), the BED+avidity screens (BED <1.0 and AI
<80%), and the MAA (see Materials and Methods). The per-
cent misclassiﬁed for the BED-CEIA was 7.6% (95% CI: 6.6%,
8.8%). Country, HIV viral load, CD4cell count, and ART were
signiﬁcantly associated with misclassiﬁcation by the BED-
CEIA (p<0.02 for all comparisons). The avidity assay mis-
classiﬁed 3.5% (95% CI: 2.7%, 4.3%) of the samples as recently
infected. Country was the only factor signiﬁcantly associated
with misclassiﬁcation (p<0.001). Using the BED+avidity
screens, 2.2% (95% CI: 1.7%, 2.9%) of the samples were mis-
classiﬁed as recently infected. With this assay combination,
country of origin and ART were signiﬁcantly associated with
misclassiﬁcation. Using the MAA, 1.2% (95% CI: 0.8%, 1.8%)
ofthesamples weremisclassiﬁed.NeitherARTnor countryof
origin was associated with misclassiﬁcation using the MAA
(p>0.37 and p>0.41, respectively). The subtype C endemic
areas (South Africa and Botswana) had signiﬁcantly lower
rates of false-recent misclassiﬁcation then the subtype A and
D endemic areas (Uganda and Kenya) for the BED-CEIA:
4.9% (95% CI: 3.2%, 7.1%) vs. 8.7% (95% CI: 7.3, 10.2%),
p=0.004, the avidity assay: 1.0% (95% CI: 0.3%, 2.2%) vs. 4.6%
(95% CI: 3.6%, 5.7%), p<0.001, and the combined BED-CEIA
and avidity screens: 1.0% (0.3% to 2.2%) vs. 2.8% (2.0% to
3.7%), p=0.017. The misclassiﬁcation rate of the MAA was
also lower in the subtype C than the A and D endemic areas;
this difference was not statistically signiﬁcant: 0.75% (95% CI:
0.21%, 1.92%) vs. 1.43% (95% CI: 0.90%, 2.17%), p=0.267.
Multivariate logistic regression was performed to compare
the odds of false-recent misclassiﬁcation by BED-CEIA alone,
the avidity assay alone, and the BED+avidity screens (Table
3); because no factors were associated with misclassiﬁcation
using the MAA (p>0.37 for all associations), the MAA results
are not shown. For the BED-CEIA, three factors were inde-
pendently associated with misclassiﬁcation: country, viral
load, and CD4cell count. The adjusted odds ratio for mis-
classiﬁcation was two times higher in Uganda and Kenya
than in South Africa. For the avidity assay, the only factor
associated with misclassiﬁcation in the multivariate model
wascountry.Theadjustedoddsratioformisclassiﬁcationwas
eight times higher in Uganda than in South Africa, and three
times higher in Kenya than in South Africa. For the
BED+avidity screens, the only factor associated with mis-
classiﬁcation in the multivariate model was country of origin,
where, for example, the adjusted odds ratio for misclassiﬁ-
cationwasapproximatelyfourtimeshigherinUgandathanin
South Africa. It is noteworthy that the strength of association
forallvariablesintheunivariateanalysiswassimilartothatin
the multivariate analysis apart from ART use. ART use was
not associated with misclassiﬁcation by the BED-CEIA, the
avidity assay, or the BED+avidity screens when the analysis
was adjusted for other variables.
Discussion
In this study, we compared false-recent misclassiﬁcation
using four different laboratory approaches for HIV inci-
dence determination. This study was based on analysis of
samples collected from ﬁve countries in East and Southern
Africa. A potential limitation of the study was that criteria
usedforstudyenrollmentmayhaveintroducedbiasintothe
cohort. All participants were HSV infected and in a stable
HIV discordant relationship; most of the participants were
Table 1. Population Characteristics by Country of Origin
Botswana Kenya South Africa Tanzania Uganda
Number of subjects 199 902 330 138 628
Mean age (SD) 35.7 (8.3) 34.2 (8.9) 33.8 (8.6) 34.8 (7.8) 34.6 (8.5)
Gender (% female) 63.82% 69.85% 74.55% 82.61% 50.48%
Pregnant 5.26% 8.22% 8.46% 8.11% 10.44%
Mean log10 viral load (SD) 3.92 (0.91) 3.80 (0.96) 3.90 (0.92) 3.95 (1.08) 4.04 (1.00)
Virally suppressed 15.58% 23.39% 15.45% 26.09% 18.95%
Taking ART 10.05% 13.41% 6.36% 5.07% 17.86%
Non-ART virally suppressed 7.26% 14.98% 13.27% 22.90% 14.34%
Mean CD4 (SD) 427 (210) 481 (240) 491 (243) 552 (285) 446 (244)
SD, standard deviation; virally suppressed, having a viral load <400copies/ml; ART, antiretroviral treatment; CD4, CD4cell count
(cells/mm
3).
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1180relatively healthy, and a substantial proportion (17%) was
virally suppressed. Additionally, the length of time that
individuals were infected was not known, although all in-
dividuals were known to have been infected for at least 1
year. In the cohort studied, the frequency of false-recent
misclassiﬁcation was 7.6% the BED-CEIA alone, 3.5% using
the avidity assay alone, 2.2% using a BED screen and an
avidity screen combined (i.e., using both assays with higher
assay cutoffs), and 1.2% using a MAA that combined the
BED screen, and avidity screen, CD4cell count, and HIV
viral load. In subtype C endemic areas, the misclassiﬁcation
frequency of the MAA was 0.8%.
In univariate models, several factors were signiﬁcantly
associated with false recent misclassiﬁcation using the BED-
CEIA alone, an avidity assay alone, or the BED+avidity
screens. These factors included country (for all three meth-
ods), HIV viral load (for BED-CEIA), CD4cell count (for BED-
CEIA), and ART use (for BED-CEIA and the BED+avidity
screens). In contrast, we did not observe any statistically sig-
niﬁcant associations between any of the factors examined and
false recentmisclassiﬁcationusingtheMAA. Inamultivariate
model, the only statistically signiﬁcant associations observed
were for country (for BED and avidity either alone or in
combination), viralload(BED-CEIAonly),andCD4cellcount
(BED-CEIA only). The association that we observed for the
BED-CEIA between misclassiﬁcation and high CD4cell count
(>500cells/mm
3) was surprising, although a previous study
from Uganda also demonstrated a similar ﬁnding among in-
dividuals on ART.
11 In previous studies, individuals with
advanced HIV disease (e.g., CD4cell counts <200cells/mm
3)
were more likely to be misclassiﬁed as recently infected
than those with higher CD4cell counts. That association was
presumed to reﬂect immunologic decline, with impaired an-
tibody production. The frequency of BED-CEIA misclassiﬁ-
cation that we observed in Uganda (8.6%) was lower than the
misclassiﬁcation frequency reported in a previous study in
Uganda (14.9%)
18; this difference may reﬂect the fact that in-
dividualsinthecohortstudiedinthisreportwerelesslikelyto
have advanced HIV disease.
In these analyses, associations between participants’
country of residence and false recent misclassiﬁcation are
likely to reﬂect differences in the prevalent HIV subtypes,
although other factors may also have inﬂuenced assay per-
formance among the countries studied. Misclassiﬁcation rates
were higher for Kenya and Uganda (East African countries
where subtypes A and D are prevalent) than for South Africa
andBotswana(SouthernAfricancountrieswheresubtypeCis
prevalent). The frequency of misclassiﬁcation was two times
higher in the subtype A and D endemic countries using the
BED-CEIA, and was four to ﬁve times higher in those coun-
tries using the avidity assay. Previous studies have shown
that HIV subtype can impact the performance of cross-
sectional incidence assays.
6,19 In South Africa and Botswana al-
most all infections are subtype C, while in Kenya and Uganda,
the most common subtypes are A and D, with some infections
caused by subtype C and A–D recombinants. In Tanzania,
Table 3. Adjusted Odds of Misclassiﬁcation for the BED-CEIA, an Avidity Assay,
and a Combined BED/Avidity Screen (Partners in Prevention Trial, Africa, 2007–2009)
BED-CEIA (OD-n <0.8) Avidity assay (AI <40%)
BED/avidity screen
(OD-n <1.0 and AI <80%)
aOR (95% CI) aOR (95% CI) aOR (95% CI)
Age
19–28 1 — —
29–33 1.44 (0.90–2.29) — —
34–39 1.44 (0.90–2.32) — —
40–70 1.21 (0.75–1.98) — —
Country
South Africa 1 1 1
Botswana 1.28 (0.57–2.89) 1.07 (0.18–6.60) 1.08 (0.18–6.58)
Tanzania 1.18 (0.57–2.81) 0.80 (0.08–7.75) 1.44 (0.24–8.76)
Kenya 1.87 (1.05–3.34)* 3.03 (0.91–10.1) 1.90 (0.55–6.59)
Uganda 2.00 (1.10–3.65)* 8.11 (2.49–26.4)
{ 4.26 (1.27–14.3)*
Viral load
>50,000 1 — 1
50,000 to 10,000 0.95 (0.54–1.70) — 0.85 (0.35–2.09)
10,000 to 400 1.20 (0.71–2.03) — 0.90 (0.38–2.10)
<400 3.49 (2.10–5.82)
{ — 2.02 (0.91–4.48)
CD4
>500 1
500–201 0.60 (0.42–0.85)
{ ——
<200 0.68 (0.31–1.20) — —
Taking ART
No 1 1 1
Yes 1.09 (0.69–1.72) 1.36 (0.76–2.45) 1.12 (0.52–2.43)
*p value<0.05.
{p value<0.01.
AI, avidity index; aOR, adjusted odds ratio; CI, conﬁdence interval; CD4, CD4cell count (cells/mm
3); viral load (copies/ml); ART,
antiretroviral therapy. Statistically signiﬁcant values (p<0.05) are shown in bold text. Values with p<0.1 (trends) are in italics.
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are prevalent.
20
This report reveals signiﬁcant differences in the rate of
false-recent misclassiﬁcation using different laboratory
methods developed for cross-sectional HIV incidence deter-
mination. The lowest misclassiﬁcation rates were observed
with the MAA (1.2% overall, 0.8% for subtype C endemic
areas). A key feature of the MAA is inclusion of two inde-
pendent serologic assays (the BED-CEIA and the avidity as-
say); this increases the speciﬁcity of the MAA for detection of
recent HIV infection. For example, when samples analyzed in
this report were tested using a similar algorithm that did
not include the BED-CEIA (with recent infection deﬁned as
avidity <80%+CD4cell count >200cells/mm
3+HIV viral
load >400copies/ml), the false-recent misclassiﬁcation rate
was four times higher that the rate obtained using the four-
assay MAA. One advantage of using the BED-CEIA and the
avidity assay for HIV incidence testing is thatthese assays can
be performed using commercially available kits (with a minor
modiﬁcation in testing procedures for the avidity assay).
Neither of these assays requires use of large, specialized
equipment, which is an advantage in resource-limited set-
tings. The avidity assay is based on the BioRad 1/2+O ELISA
kit, which was designed for diagnosis of HIV infection. The
target antigens in this kit are large polypeptides (p24 and
gp160) that include multiple antigens that are recognized by
anti-HIV antibodies from individuals infected with diverse
HIV strains.
21 This assay is used globally for diagnosis of HIV
infection and performs well across all subtypes for the de-
tection on anti-HIV antibodies. Our results demonstrate that
the avidity assay based on the BioRad 1/2+O ELISA has a
relatively low rate of false-recent misclassiﬁcation when
samples are analyzed from African individuals who are likely
to be infected with different HIV subtypes.
A disadvantage of the MAA is the requirement for CD4cell
countdata.Storageofcryopreservedsamplesthatcanbeused
forretrospectiveCD4testingiscostlyandnotfeasibleinmany
settings. Therefore, in most settings, CD4cell count data must
be obtained at the time of sample collection. We are cur-
rently evaluating whether CD4 testing can be replaced in the
MAA by a high resolution melting (HRM) assay that mea-
sures HIV diversity without sequencing,
22 which can be per-
formed using stored serum or plasma samples. In the MAA,
viral load testing is needed only for a small subset of samples
(i.e., those with BED-CEIA <1.0 OD-n+avidity <80%+CD4
>200cells/mm
3). This is an advantage, since HIV viral load
testsarethemostexpensivecomponentoftheMAA.Wefeelit
isimportanttoincludeadirectmeasurementofHIVviralload
intheMAA,rather thanrelyingonself-reportofantiretroviral
drug (ARV) use as a surrogate of viral suppression. Self-
reports of ARV use may be unreliable, and some individuals
on ARV therapy may not be virally suppressed. Furthermore,
our previous studies have shown a high rate of false-recent
misclassiﬁcation among HIV-infected elite suppressors who
have low or undetectable viral loads in the absence of ARV
use.
23 In this study, ARV use was not associated with false-
recent misclassiﬁcation in multivariate models that also
included HIV viral load.
This report is focused on the speciﬁcity of laboratory
methods for HIV incidence determination. The speciﬁcity of
HIV incidence algorithms substantially impacts their perfor-
mance, since the number of prevalent infections is usually
much greater than the number of incident infections. We
recognize, however, that the sensitivity for detecting recent
infections is also an important indicator of test performance.
Furthermore, our nonrecent samples included only those
samples with duration of infection >12 months. The operat-
ing characteristics (i.e., sensitivity and speciﬁcity) of the MAA
are expected to vary with different deﬁnitional criteria for
recent versus nonrecent infections based on duration of in-
fection. Further studies are needed to assess the sensitivity of
the MAA in detecting recent HIV infection, the window
length for differentiating recent versus nonrecent infection,
and whether sensitivity varies by subtype.
Acknowledgments
The authors would like to thank the Partners in Prevention
study teams and participants, S. Michelle Owen (United
StatesCentersforDiseaseControlandPrevention),ErinKahle
(University of Washington), Harald S. Haugen (University of
Washington), and Amy Mueller (Johns Hopkins University).
This work was supported by (1) the HIV Prevention Trials
Network (HPTN) sponsored by the National Institute of Al-
lergy and Infectious Diseases (NIAID), the National Institute
of Mental Health (NIMH), the National Institute on Drug
Abuse (NIDA), Ofﬁce of AIDS Research, of the National In-
stitutes of Health (NIH), Department of Health and Human
Services (DHHS) (Grants U01-AI46745, U01-AI48054,
U01-AI068613, and UM1-AI068613), and the International
Maternal Pediatric and Adolescent AIDS Clinical Trials
(IMPAACT) Network (U01-AI068632), (2) the Division of
Intramural Research, NIAID, (3) the NIAID (Grant 1R01-
AI095068), and (4) the Bill and Melinda Gates Foundation
(Grant 26469).
The ﬁndings and conclusions in this article are those of the
authors and do not necessarily represent the views of the
National Institutes of Health. Use of trade names is for iden-
tiﬁcation purposes only and does not constitute endorsement
by the National Institutes of Health and Prevention or the
Department of Health and Human Services.
Author Disclosure Statement
No competing ﬁnancial interests exist.
References
1. Brookmeyer R: Measuring the HIV/AIDS epidemic: Ap-
proaches and challenges. Epidemiol Rev 2010;32:26–37.
2. Murphy G and Parry JV: Assays for the detection of recent
infections with human immunodeﬁciency virus type 1. Euro
Surveill 2008;13:pii18966.
3. Busch MP, Pilcher CD, Mastro TD, Kaldor J, Vercauteren G,
Rodriguez W, et al.: Beyond detuning: 10 years of progress
and new challenges in the development and application of
assays for HIV incidence estimation. AIDS 2010;24:2763–2771.
4. Dobbs T, Kennedy S, Pau CP, McDougal JS, and Parekh BS:
Performance characteristics of the immunoglobulin G-
capture BED-enzyme immunoassay, an assay to detect re-
cent human immunodeﬁciency virus type 1 seroconversion.
J Clin Microbiol 2004;42:2623–2628.
5. Masciotra S, Dobbs T, Candal D, Hanson D, Delaney K,
Rudolph D, et al.: Antibody avidity-based assay for identi-
fying recent HIV-1 infections based on Genetic Systems TM
1/2 plus O EIA. 17th Conference on Retroviruses and
1182 LAEYENDECKER ET AL.Opportunistic Infections, Abstract 937. San Francisco, CA,
February 16–19, 2010.
6. Parekh BS, Hanson DL, Hargrove J, Branson B, Green T,
Dobbs T, et al.: Determination of mean recency period for
estimation of HIV type 1 incidence with the BED-Capture
EIA in persons infected with diverse subtypes. AIDS Res
Hum Retroviruses 2011;27:265–273.
7. UNAIDS Reference Group on Estimates, Modeling, and
Projections: Statement on the use of the BED assay for esti-
mation of HIV-1 incidence or epidemic monitoring. Weekly
Epidemiol Rec 2006;81:33–40.
8. Barnighausen T, Wallrauch C, Welte A, McWalter TA,
Mbizana N, Viljoen J, et al.: HIV incidence in rural South
Africa: Comparison of estimates from longitudinal surveil-
lance and cross-sectional cBED assay testing. PLoS One
2008;3:e3640.
9. Karita E, Price M, Hunter E, Chomba E, Allen S, Fei L, et al.:
Investigating the utility of the HIV-1 BED capture en-
zyme immunoassay using cross-sectional and longitudi-
nal seroconverter specimens from Africa. AIDS 2007;21:
403–408.
10. Marinda ET, Hargrove J, Preiser W, Slabbert H, van Zyl G,
Levin J, et al.: Signiﬁcantly diminished long-term speciﬁcity
of the BED capture enzyme immunoassay among patients
with HIV-1 with very low CD4 counts and those on anti-
retroviral therapy. J Acquir Immune Deﬁc Syndr 2010;53:
496–499.
11. Hladik W, Olara D, Mermin J, Moore D, Were W, Alexander
L, and Downing R: Effect of CD4+ T-cell count and anti-
retroviral treatment on two serological HIV incidence as-
says. AIDS Res Hum Retroviruses 2012;28(1):5–99.
12. Hayashida T, Gatanaga H, Tanuma J, and Oka S: Effects of
low HIV type 1 load and antiretroviral treatment on IgG-
capture BED-enzyme immunoassay. AIDS Res Hum Retro-
viruses 2008;24:495–498.
13. Incidence Assay Critical Path Working Group: More and
better information to tackle HIV epidemics: Towards im-
proved HIV incidence assays. PLoS Med 2011;8:e1001045.
14. Braunstein SL, Nash D, Kim AA, Ford K, Mwambarangwe
L, Ingabire CM, et al.: Dual testing algorithm of BED-CEIA
and AxSYM Avidity Index assays performs best in identi-
fying recent HIV infection in a sample of Rwandan sex
workers. PLoS One 2011;6:e18402.
15. Celum C, Wald A, Lingappa JR, Magaret AS, Wang RS,
Mugo N, et al.: Acyclovir and transmission of HIV-1 from
persons infected with HIV-1 and HSV-2. N Engl J Med
2010;362:427–439.
16. Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E,
et al.: Use of hormonal contraceptives and risk of HIV-1
transmission: A prospective cohort study. Lancet Infect Dis
2012;12:19–26.
17. Parekh BS, Kennedy MS, Dobbs T, Pau CP, Byers R, Green T,
et al.: Quantitative detection of increasing HIV type 1 anti-
bodies after seroconversion: A simple assay for detecting
recent HIV infection and estimating incidence. AIDS Res
Hum Retroviruses 2002;18:295–307.
18. Kim AA, Hallett T, Stover J, Gouws E, Musinguzi J, Mureithi
PK, et al.: Estimating HIV incidence among adults in Kenya
and Uganda: A systematic comparison of multiple methods.
PLoS One 2011;6:e17535.
19. Young CL, Hu DJ, Byers R, Vanichseni S, Young NL, Nelson
R, et al.: Evaluation of a sensitive/less sensitive testing al-
gorithm using the bioMerieux Vironostika-LS assay for de-
tecting recent HIV-1 subtype B’ or E infection in Thailand.
AIDS Res Hum Retroviruses 2003;19:481–486.
20. Hemelaar J, Gouws E, Ghys PD, and Osmanov S: Global
trends in molecular epidemiology of HIV-1 during 2000–
2007. AIDS 2011;25:679–689.
21. Owen SM, Yang C, Spira T, Ou CY, Pau CP, Parekh BS, et al.:
Alternative algorithms for human immunodeﬁciency virus
infection diagnosis using tests that are licensed in the United
States. J Clin Microbiol 2008;46:1588–1595.
22. Cousins MM, Laeyendecker O, Beauchamp G, Brookmeyer
R, Towler WI, Hudelson SE, et al.: Use of a high resolution
melting (HRM) assay to compare gag, pol, and env diversity
in adults with different stages of HIV infection. PLoS One
2011;6:e27211.
23. Laeyendecker O, Rothman RE, Henson C, Horne BJ, Ketlo-
getswe KS, Kraus CK, et al.: The effect of viral suppression
on cross-sectional incidence testing in the Johns Hopkins
Hospital Emergency Department. J Acquir Immune Deﬁc
Syndr 2008;48:211–215.
Address correspondence to:
Oliver Laeyendecker
Senior Research Associate, LIR/NIAID/NIH
855 North Wolfe Street, Room 538A
Baltimore, Maryland 21205
E-mail: olaeyen1@jhmi.edu
SPECIFICITY OF THE BED-CEIA AND BIORAD AVIDITY IN AFRICA 1183